VKTX VK2735 New Data at Obesity Week 2024
Obesity Week 2024 is abuzz with Viking Therapeutics' oral VK2735 (GLP-1/GIP Co-Agonist) new data from its multiple ascending dose cohorts and additional VK2735 subQ data.
📉 Price down -13.36% at close 11/4
💊 VK2735 Oral 60, 80, 100 mg cohorts
» Up to 8.2% wt loss from baseline in 28 days (placebo-adjusted mean up to 6.8%)
» Wt loss persisted to Day 57, suggesting potential for continued benefits
» Encouraging safety and tolerability data, even at 100 mg dose
💉VK2735 SubQ VENTURE Ph2
» Up to 14.7% mean body wt reduction after 13 weeks
» Statistically significant wt loss from week 1, w/ no plateau in reductions
» 7-week follow-up showed 80% wt loss retention - supports once-monthly maintenance dosing
See images for more details 📸 👇
Below are some of Biopharma community's interesting thoughts on X...
⏰ Limited Time Offer (Ends on 11/3):
Become a BPIQ Elite member with our 🎃 Halloween Sale (50% Off) & get...
All catalyst & PDUFA dates!
Big/Suspected Movers
Hedge fund analysis & M&A data!
Stock ideas from our model portfolio!
🔐 Lock in the discount with a free trial!
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 11/04/24 EJV, JD, AV, & DG